Literature DB >> 33558454

Inhibition of cystathionine β-synthase promotes apoptosis and reduces cell proliferation in chronic myeloid leukemia.

Dan Wang1, Huan Yang1, Yun Zhang2, Rong Hu1, Dongjie Hu1, Qunxian Wang1, Yannan Liu1, Mingjing Liu1, Zijun Meng1, Weihui Zhou1, Weihong Song3,4.   

Abstract

Increased endogenous hydrogen sulfide (H2S) level by cystathionine β-synthase (CBS) has been shown to closely relate tumorigenesis. H2S promotes angiogenesis, stimulates bioenergy metabolism and inhibits selective phosphatases. However, the role of CBS and H2S in chronic myeloid leukemia (CML) remains elusive. In this study, we found that CBS and H2S levels were increased in the bone marrow mononuclear cells of pediatric CML patients, as well as in the CML-derived K562 cells and CBS expression levels were correlated with different disease phases. Inhibition of CBS reduced the proliferation of the CML primary bone marrow mononuclear cells and induced growth inhibition, apoptosis, cell cycle arrest, and migration suppression in K562 cells and tumor xenografts. The knockdown of CBS expression by shRNA and inhibiting CBS activity by AOAA decreased the endogenous H2S levels, promoted mitochondrial-related apoptosis and inhibited the NF-κB-mediated gene expression. Our study suggests that inhibition of CBS induces cell apoptosis, as well as limits cell proliferation and migration, a potential target for the treatment of chronic myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33558454      PMCID: PMC7870845          DOI: 10.1038/s41392-020-00410-5

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  70 in total

1.  Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells.

Authors:  Hui Guo; Jun-Wei Gai; Ying Wang; Hong-Fang Jin; Jun-Bao Du; Jie Jin
Journal:  Urology       Date:  2012-02       Impact factor: 2.649

2.  Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation.

Authors:  T S Finco; J K Westwick; J L Norris; A A Beg; C J Der; A S Baldwin
Journal:  J Biol Chem       Date:  1997-09-26       Impact factor: 5.157

3.  Hydrogen sulfide-linked sulfhydration of NF-κB mediates its antiapoptotic actions.

Authors:  Nilkantha Sen; Bindu D Paul; Moataz M Gadalla; Asif K Mustafa; Tanusree Sen; Risheng Xu; Seyun Kim; Solomon H Snyder
Journal:  Mol Cell       Date:  2012-01-13       Impact factor: 17.970

4.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

5.  Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.

Authors:  Daniela S Bassères; Aaron Ebbs; Elena Levantini; Albert S Baldwin
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

6.  Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB).

Authors:  M Hamdane; M H David-Cordonnier; J C D'Halluin
Journal:  Oncogene       Date:  1997-11-06       Impact factor: 9.867

7.  Fluorescent probe for highly selective and sensitive detection of hydrogen sulfide in living cells and cardiac tissues.

Authors:  Bifeng Chen; Wei Li; Cong Lv; Manman Zhao; Hongwei Jin; Hongfang Jin; Junbao Du; Liangren Zhang; Xinjing Tang
Journal:  Analyst       Date:  2013-02-21       Impact factor: 4.616

Review 8.  Optimal management for pediatric chronic myeloid leukemia.

Authors:  Akihiko Tanizawa
Journal:  Pediatr Int       Date:  2016-03       Impact factor: 1.524

9.  Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.

Authors:  Dieter Kirchner; Justus Duyster; Oliver Ottmann; Roland M Schmid; Lothar Bergmann; Gerd Munzert
Journal:  Exp Hematol       Date:  2003-06       Impact factor: 3.084

10.  The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.

Authors:  Enza Di Felice; Francesca Roncaglia; Francesco Venturelli; Lucia Mangone; Stefano Luminari; Claudia Cirilli; Giuliano Carrozzi; Paolo Giorgi Rossi
Journal:  BMC Cancer       Date:  2018-11-06       Impact factor: 4.430

View more
  6 in total

1.  Pharmacological Inhibition of Endogenous Hydrogen Sulfide Attenuates Breast Cancer Progression.

Authors:  Nazeer Hussain Khan; Di Wang; Wenkang Wang; Muhammad Shahid; Saadullah Khattak; Ebenezeri Erasto Ngowi; Muhammad Sarfraz; Xin-Ying Ji; Chun-Yang Zhang; Dong-Dong Wu
Journal:  Molecules       Date:  2022-06-23       Impact factor: 4.927

2.  A hydrogen sulphide-responsive and depleting nanoplatform for cancer photodynamic therapy.

Authors:  Yuqi Zhang; Jing Fang; Shuyue Ye; Yan Zhao; Anna Wang; Qiulian Mao; Chaoxiang Cui; Yali Feng; Jiachen Li; Sunao Li; Mingyang Zhang; Haibin Shi
Journal:  Nat Commun       Date:  2022-03-30       Impact factor: 17.694

3.  Sulfurtransferases and Cystathionine Beta-Synthase Expression in Different Human Leukemia Cell Lines.

Authors:  Halina Jurkowska; Maria Wróbel; Ewa Jasek-Gajda; Leszek Rydz
Journal:  Biomolecules       Date:  2022-01-18

4.  Cystathionine β-Synthase Regulates the Proliferation, Migration, and Invasion of Thyroid Carcinoma Cells.

Authors:  Qi-Ying Jiang; Jian-Mei Li; Mi-Rong Jing; Yan-Xia Zhang; Qian-Qian Zhang; Chun-Bo Cai; Di Wang; Hui-Wen Qi; Tao Li; Yan-Zhang Li; Xin-Ying Ji; Dong-Dong Wu
Journal:  Oxid Med Cell Longev       Date:  2022-06-27       Impact factor: 7.310

Review 5.  Targeting Amino Acid Metabolic Vulnerabilities in Myeloid Malignancies.

Authors:  Livingstone Fultang; Luciana Gneo; Carmela De Santo; Francis J Mussai
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 6.  Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias.

Authors:  Aboli Bhingarkar; Hima V Vangapandu; Sanjay Rathod; Keito Hoshitsuki; Christian A Fernandez
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.